Key Points
- Klick Health has completed its third takeover in 18 months by acquiring Oxford PharmaGenesis.
- The Toronto-based agency is expanding its global reach and strengthening scientific expertise.
- Oxford PharmaGenesis is a U.K.-based healthcare communications consultancy with more than 500 employees.
- The consultancy brings medical affairs, market access, oncology, rare disease, real-world evidence, and health economics expertise.
- Klick says its own medical, creative, and digital capabilities will support Oxford PharmaGenesis after the deal.
- The acquisition increases Klick’s footprint to 12 offices across North America, the U.K., Australia, Brazil, and Singapore.
- The move follows Klick’s earlier purchases of Peregrine Market Access and Ward6 Singapore’s operations.
- Klick also received growth investment from Linden Capital Partners and GIC to support expansion.
- Both companies have recently gained external recognition in the healthcare communications sector.
Oxford (Oxford Daily) June 30, 2026 – Klick Health has acquired Oxford PharmaGenesis in what the company describes as its biggest takeover yet, extending a rapid expansion strategy that began only last year. The Toronto-based marketing agency, founded in 1997, had stayed out of mergers and acquisitions for most of its history before moving into dealmaking early in 2025.
The latest purchase follows the earlier acquisitions of Peregrine Market Access and Ward6 Singapore’s operations, marking a sharp shift in the company’s growth approach. One year after receiving growth investment from Linden Capital Partners and GIC, Klick has used its stronger financial backing to deepen its position in healthcare communications and life sciences services.
Why Oxford PharmaGenesis?
The deal brings Oxford PharmaGenesis into Klick’s network as a U.K.-based healthcare communications consultancy with more than 500 staff across North America, Europe and Asia-Pacific. Klick said Oxford PharmaGenesis adds strength in medical affairs and market access, two areas that are increasingly important in pharmaceutical communications and commercial strategy.
Oxford PharmaGenesis also brings scientific expertise in oncology and rare disease, along with capabilities in real-uk/world/">world evidence and health economics and outcomes research. Those specialisms are likely to complement Klick’s existing medical, creative and digital services, which the agency identified as a reason the acquisition makes strategic sense.
How large is the new footprint?
The takeover expands Klick’s reach to 12 offices across North America, the U.K., Australia, Brazil and Singapore. That footprint reflects a broader global expansion plan that began in 2022, when the company announced ambitions to open offices in Asia-Pacific, Europe and Latin America.
Klick opened a hub in Singapore in 2023 and later bought Ward6’s operations there in 2025, showing a clear focus on building a stronger Asia-Pacific presence. Oxford PharmaGenesis also contributes to that international push, with offices in several U.K. cities plus a presence in Melbourne and the United States.
What does this mean strategically?
The acquisition suggests Klick is building a more integrated healthcare communications business that combines scientific depth, geographic reach and creative services. By adding Oxford PharmaGenesis, Klick is not only growing larger but also broadening the range of services it can offer to pharmaceutical and biotech clients.
The timing also matters because both companies have recently gained external recognition. Klick won major honours at the Cannes Lions Festival of Creativity, becoming the first company to sweep the top health agency trophies, while Oxford PharmaGenesis has long promoted its international reputation and specialist expertise.
Background of the development
Klick’s move into acquisitions marks a major change for a company that spent most of its history outside M&A activity. The shift began in early 2025 with the purchase of Peregrine Market Access and continued with Ward6 Singapore’s operations, followed by new growth investment from Linden Capital Partners and GIC.
The Oxford PharmaGenesis acquisition appears to be the most significant step yet in that expansion strategy. It reflects a trend among healthcare agencies to compete not only on creative work, but also on scientific expertise, market access knowledge and international delivery capability.
Prediction for the market?
For pharmaceutical and healthcare clients, this deal could mean more consolidated service offerings from a single agency group, especially for projects that need both scientific and creative support. It may also increase competition among other healthcare communications firms that now face a larger and more globally distributed Klick.
For audiences in the healthcare marketing sector, the likely effect is continued consolidation, with well-capitalised agencies using acquisitions to broaden expertise and geographic coverage. If Klick continues on this path, its influence in global healthcare communications may grow further, especially in markets where medical affairs, market access and scientific storytelling are becoming more important.
